HBOT reduced a future dementia marker of mine by 28%. Details: + pTAU217 just got FDA-clea

Well SupportedpTau217 and Aβ42 are FDA-approved biomarkers for Alzheimer's detection in symptomatic patients and can predict future dementia risk in healthy individuals.

Well SupportedElevated blood p-Tau217 levels in healthy individuals may warrant further brain imaging for Alzheimer's risk assessment.

Partially SupportedThe Lumipulse G test is an FDA-approved blood test for early Alzheimer's detection in symptomatic individuals over 55.

Partially SupportedThe speaker's pTAU217 level decreased from 0.14 to 0.10 pg/mL after HBOT.